| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥68.4B | ¥79.5B | -14.0% |
| Operating Income | ¥-12.8B | ¥-3.3B | -284.6% |
| Ordinary Income | ¥-12.3B | ¥-2.6B | -372.4% |
| Net Income | ¥-15.5B | ¥-3.2B | -389.4% |
| ROE | -27.4% | -4.4% | - |
FY2026 Q3 cumulative results show revenue of 68.4B yen (YoY -14.0%), operating loss of -12.8B yen (prior year -3.3B yen, deterioration of -284.6%), ordinary loss of -12.3B yen (prior year -2.6B yen, deterioration of -372.4%), and net loss of -15.5B yen (prior year -3.2B yen, deterioration of -389.4%). The company underwent organizational restructuring in April 2025, consolidating from two reporting segments (CRO business and drug development business) into a single CRO business segment. Revenue declined by 11.1B yen YoY while operating loss expanded by 9.5B yen, indicating deteriorating profitability amid shrinking top-line. Gross profit margin stands at 16.2% while SG&A expenses account for 34.9% of revenue, creating a significant structural deficit. Non-operating items contributed marginally positive with interest income of 0.4B yen and FX gains of 0.4B yen offsetting interest expenses and FX losses. Tax expense of 3.2B yen was recorded despite pre-tax loss, resulting in net loss expansion. Basic EPS deteriorated to -68.68 yen from -14.03 yen YoY. The company maintains full-year guidance of revenue 93.5B yen (YoY -10.4%) and net loss of -17.0B yen with year-end dividend of 16.00 yen unchanged.
Revenue decreased 11.1B yen YoY to 68.4B yen, representing a contraction of 14.0%. The company transitioned to a single CRO business segment during Q1 following organizational changes in April 2025, consolidating the previously separate drug development business. This restructuring reflects management's reassessment of resource allocation and performance evaluation frameworks. The revenue decline suggests challenges in order intake or project execution velocity within the core CRO operations. Cost of sales amounted to 57.3B yen, yielding gross profit of 11.1B yen with a gross margin of 16.2%, down from healthier levels in prior periods. This compression indicates either pricing pressure, unfavorable project mix, or operational inefficiencies.
SG&A expenses totaled 23.9B yen, representing 34.9% of revenue and exceeding gross profit by 12.8B yen, which directly drove the operating loss of -12.8B yen. The operating margin deteriorated to -18.7% from -4.2% in the prior year, indicating a significant profitability inflection point. The magnitude of SG&A relative to gross profit suggests fixed cost burden has not been rightsized in line with revenue contraction, representing the primary driver of operating loss expansion.
Non-operating items provided modest relief with net contribution of approximately 0.5B yen. Interest income of 0.4B yen and FX gains of 0.4B yen within non-operating income of 1.0B yen were partially offset by interest expense of 0.1B yen and FX losses of 0.4B yen within non-operating expenses of 0.6B yen. This resulted in ordinary loss of -12.3B yen.
The gap between ordinary loss of -12.3B yen and net loss of -15.5B yen amounts to -3.2B yen, which is explained by income tax expense of 3.2B yen recorded against pre-tax loss of -12.3B yen. This tax expense despite losses likely reflects non-deductible items, deferred tax adjustments, or separate taxable entities within the consolidated group.
This represents a revenue down, profit down deterioration pattern, with both top-line contraction and significant operating leverage working in reverse to amplify bottom-line losses.
The company operates a single CRO business segment following the consolidation of the previously separate drug development business in Q1 FY2026. Segment-level operating profit breakdown is not disclosed as the company now reports consolidated results as one unified business. The CRO business represents 100% of consolidated revenue and operating results, making it the core business by definition. Prior year comparative segment data is not provided due to the reporting structure change.
[Profitability] ROE of -27.4% reflects substantial loss generation against declining equity base. Operating margin deteriorated to -18.7% from -4.2% YoY, driven by gross margin compression to 16.2% and SG&A ratio expansion to 34.9% of revenue. Net profit margin stands at -22.7%, indicating approximately 22.7 yen loss per 100 yen of revenue. DuPont decomposition shows net profit margin of -22.7%, asset turnover of 0.489, and financial leverage of 2.47 combining to produce the negative ROE. [Cash Quality] Cash and deposits amount to 51.5B yen, decreased 18.9B yen or 26.8% YoY, representing coverage of 5.4 times against short-term borrowings of 9.5B yen. Trade receivables stand at 24.0B yen with days sales outstanding calculated at approximately 128 days, indicating extended collection cycles. Operating working capital of 27.0B yen suggests positive net working capital position but with collection timing concerns. [Investment Efficiency] Total asset turnover of 0.489 indicates revenue generation of approximately 0.49 yen per yen of assets, below industry median of 0.67. Intangible assets including goodwill total 31.5B yen with goodwill specifically at 30.7B yen, representing 54.1% of total equity and posing impairment risk given loss-making status. [Financial Health] Equity ratio of 40.5% reflects total equity of 56.7B yen against total assets of 139.9B yen, with debt-to-equity ratio of 1.47. Current ratio stands at 141.3% with current assets of 92.5B yen covering current liabilities of 65.5B yen. Short-term debt represents 54.3% of total liabilities, indicating concentration of repayment obligations. Long-term loans decreased to 8.0B yen from 11.0B yen YoY while short-term borrowings increased to 9.5B yen from 6.0B yen, suggesting potential debt maturity migration. Retained earnings decreased 19.1B yen to 45.2B yen due to cumulative loss absorption.
Cash and deposits decreased 18.9B yen YoY to 51.5B yen, representing a 26.8% decline that reflects substantial cash outflow during the nine-month period. The cash reduction occurred despite short-term borrowings increasing 3.5B yen to 9.5B yen, suggesting operating activities consumed significant liquidity. Working capital movements show trade receivables at 24.0B yen with extended collection cycles of approximately 128 days, indicating cash conversion challenges from revenue generation. Current liabilities increased marginally while long-term loans decreased 3.0B yen from 11.0B yen to 8.0B yen, indicating debt repayment activity that contributed to cash utilization. The combination of operating losses totaling 12.8B yen, extended receivables collection, and long-term debt repayment of 3.0B yen substantially explain the 18.9B yen cash decline. Short-term liquidity coverage remains adequate with cash-to-short-term borrowings ratio of 5.4 times, though the trajectory of cash consumption warrants close monitoring. Retained earnings decreased 19.1B yen primarily due to net loss of 15.5B yen, with the remainder potentially attributable to dividend payments. The cash position deterioration pattern indicates that without meaningful operating performance recovery or additional financing, liquidity buffers will continue to compress over subsequent periods.
Ordinary loss of -12.3B yen versus operating loss of -12.8B yen indicates net non-operating contribution of approximately 0.5B yen or 0.7% of revenue. Non-operating income of 1.0B yen comprises primarily interest income of 0.4B yen and FX gains of 0.4B yen, representing core treasury and foreign currency transaction results rather than extraordinary items. Non-operating expenses of 0.6B yen include interest expense of 0.1B yen and FX losses of 0.4B yen, with net financial costs being modest relative to revenue scale. The consistency between operating loss and ordinary loss confirms that core business performance drives overall results without material distortion from financial activities. The divergence between ordinary loss of -12.3B yen and net loss of -15.5B yen stems from income tax expense of 3.2B yen recorded against pre-tax losses, suggesting tax items not aligned with current period economics such as deferred tax adjustments or non-deductible expenses. No extraordinary losses were recorded in the current period beyond 0.0B yen disposal losses. Comprehensive income of -12.2B yen includes FX translation adjustment gain of 3.5B yen partially offsetting the net loss, along with minor valuation differences on securities of -0.1B yen and remeasurement of defined benefit plans of -0.1B yen. Operating cash flow data is not disclosed in quarterly reporting, limiting direct assessment of cash earnings quality. However, the 18.9B yen cash decrease and 128-day receivables collection cycle raise concerns about working capital efficiency and cash generation capability underlying reported losses. The absence of material non-recurring items confirms that the reported losses reflect sustained operational challenges rather than one-time charges.
The company maintains full-year FY2026 guidance of revenue 93.5B yen (YoY -10.4%), operating loss of -13.5B yen, ordinary loss of -14.0B yen, and net loss of -17.0B yen with annual dividend of 16.00 yen. No revisions were made during Q3. Through Q3, revenue of 68.4B yen represents 73.1% progress against full-year guidance, operating loss of -12.8B yen represents 94.8% of expected full-year loss, and net loss of -15.5B yen already represents 91.2% of full-year guidance. The high loss recognition rate through nine months suggests Q4 performance improvement is embedded in guidance assumptions, or that guidance may face downward revision risk if current loss trajectory persists. Standard quarterly progress for nine months would be 75% for revenue and similar proportional recognition for profits. Revenue progress of 73.1% is slightly below standard, indicating Q4 revenue acceleration of approximately 25.1B yen would be required to meet the 93.5B yen target. Operating loss already approaching 95% of full-year guidance suggests limited margin for Q4 deterioration. The company's forecast assumes sequential improvement in Q4 to limit full-year losses to guided levels, though visibility into this recovery is unclear from disclosed data. Forecast notes indicate that forward-looking statements are based on currently available information and reasonable assumptions, with actual results potentially differing materially. No specific drivers or assumptions underlying the Q4 recovery expectation are disclosed.
The company maintains year-end dividend guidance of 16.00 yen per share despite recording net loss of -15.5B yen through Q3 and projecting full-year net loss of -17.0B yen. Based on forecasted EPS of -75.27 yen, the dividend payout ratio calculates to negative 21.3%, which is not economically meaningful as dividends are paid from retained earnings or cash reserves rather than current period profits. Retained earnings decreased 19.1B yen YoY to 45.2B yen, reflecting absorption of the 15.5B yen net loss plus approximately 3.6B yen of dividend distributions from prior period authorizations. At 16.00 yen per share on approximately 22,586 thousand average shares, total dividend payment would amount to approximately 3.6B yen, representing 7.0% of cash and deposits of 51.5B yen or 8.0% of retained earnings of 45.2B yen. While absolute cash coverage appears adequate in the near term, the continuation of dividends amid sustained losses and declining cash balances raises questions about medium-term sustainability. No share buyback activity is disclosed. Total shareholder return consists solely of dividends, representing 8.0% distribution from retained earnings base. The dividend policy maintaining 16.00 yen suggests management confidence in business stabilization or commitment to shareholder returns regardless of near-term profitability challenges, though investors should monitor cash flow generation and operating performance recovery as indicators of distribution sustainability.
Business concentration risk exists following consolidation into single CRO business segment in April 2025, increasing dependence on pharmaceutical industry client demand, clinical trial volumes, and project success rates without diversification buffer from previously separate drug development operations. Any sustained downturn in pharmaceutical R&D spending or loss of major clients would directly impact revenue and profitability without offsetting segments.
Operating leverage risk manifests through SG&A expenses of 23.9B yen exceeding gross profit of 11.1B yen by 12.8B yen, with SG&A representing 34.9% of revenue. This cost structure creates significant operating losses at current revenue levels, requiring either 14% revenue growth to approximately 78B yen annualized or 12.8B yen SG&A reduction to achieve breakeven, absent gross margin improvement. Continued revenue pressure would amplify losses.
Goodwill impairment risk arises from 30.7B yen goodwill representing 54.1% of total equity of 56.7B yen, combined with sustained operating losses of 12.8B yen and declining business performance. If cash flow projections supporting goodwill carrying value are not achieved, material impairment charges could further erode equity and potentially trigger covenant breaches or capital adequacy concerns, particularly given current loss-making status and declining retained earnings.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE of -27.4% versus industry median of 8.3% (2025-Q3, n=104) indicates substantial underperformance. Operating margin of -18.7% compares unfavorably to industry median of 8.2% (IQR: 3.6%-18.0%), positioning the company in the bottom tier of profitability. Net profit margin of -22.7% versus industry median of 6.0% (IQR: 2.2%-12.7%) confirms significant margin disadvantage.
Financial Health: Equity ratio of 40.5% falls below industry median of 59.2% (IQR: 42.5%-72.7%), indicating relatively higher financial leverage. Current ratio of 141.3% is below industry median of 215.0% (IQR: 157.0%-362.0%), suggesting tighter liquidity positioning compared to peers.
Efficiency: Asset turnover of 0.489 is below industry median of 0.67 (IQR: 0.49-0.93), indicating lower asset utilization efficiency. Receivables turnover of approximately 128 days significantly exceeds industry median of 61.25 days (IQR: 45.96-82.69 days), highlighting extended collection cycles as a competitive weakness.
Growth: Revenue decline of -14.0% YoY contrasts sharply with industry median revenue growth of 10.4% (IQR: -1.2% to 19.6%), positioning the company among the bottom performers in top-line expansion.
The company's financial metrics consistently underperform industry benchmarks across profitability, efficiency, growth, and to a lesser extent financial health, indicating structural challenges requiring operational turnaround and strategic repositioning to align with peer performance levels.
(Industry: IT and Telecommunications (104 companies), Comparison: Prior fiscal periods, Source: Proprietary analysis)
Operating loss expanded significantly to -12.8B yen from -3.3B yen YoY with operating margin deteriorating to -18.7%, driven by revenue contraction of 14.0% to 68.4B yen and SG&A expenses of 23.9B yen exceeding gross profit of 11.1B yen by 12.8B yen. This structural unprofitability at current revenue levels represents the primary characteristic requiring immediate management attention through either top-line recovery or cost restructuring.
Extended receivables collection cycle of 128 days significantly exceeds industry median of 61 days, indicating working capital management challenges that compound cash flow pressure alongside operating losses. Combined with cash and deposits declining 26.8% YoY to 51.5B yen, the trajectory suggests liquidity consumption that warrants close monitoring despite current coverage of 5.4 times short-term borrowings.
Goodwill of 30.7B yen representing 54.1% of total equity of 56.7B yen creates material impairment risk given sustained loss-making operations, with potential for further equity erosion if business performance does not stabilize. Retained earnings already declined 29.7% YoY to 45.2B yen, with continued dividend payments of 16.00 yen per share representing 8.0% distribution against shrinking retained earnings base, raising medium-term sustainability questions absent operating recovery.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.